Caricamento...

Efficacy and Safety of Afatinib for EGFR-mutant Non-small Cell Lung Cancer, Compared with Gefitinib or Erlotinib

PURPOSE: We tried to evaluate whether there are any specific features in treatment outcomes of firstline afatinib in patients with epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC), compared with gefitinib or erlotinib. MATERIALS AND METHODS: We analyzed patients trea...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Cancer Res Treat
Autori principali: Kim, Youjin, Lee, Se-Hoon, Ahn, Jin Seok, Ahn, Myung-Ju, Park, Keunchil, Sun, Jong-Mu
Natura: Artigo
Lingua:Inglês
Pubblicazione: Korean Cancer Association 2019
Soggetti:
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6473268/
https://ncbi.nlm.nih.gov/pubmed/29898592
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4143/crt.2018.117
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !